Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mersana Therapeutics Q1 2024 GAAP EPS $(0.16) Beats $(0.19) Estimate, Sales $9.245M Beat $8.500M Estimate

Author: Benzinga Newsdesk | May 09, 2024 07:11am
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.19) by 15.79 percent. The company reported quarterly sales of $9.245 million which beat the analyst consensus estimate of $8.500 million by 8.76 percent. This is a 18.50 percent increase over sales of $7.802 million the same period last year.

Posted In: MRSN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist